Incyte Financials
| INCY Stock | USD 70.39 0.66 0.93% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.63 | 3.7451 |
|
|
The financial analysis of Incyte is a critical element in measuring its lifeblood. Investors should not minimize Incyte's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Incyte | Select Account or Indicator |
Understanding current and past Incyte Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Incyte's financial statements are interrelated, with each one affecting the others. For example, an increase in Incyte's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Incyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Incyte. Check Incyte's Beneish M Score to see the likelihood of Incyte's management manipulating its earnings.
Incyte Stock Summary
Incyte competes with Alnylam Pharmaceuticals, United Therapeutics, Ultragenyx, Apellis Pharmaceuticals, and BeiGene. Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Incyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2094 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US45337C1027 |
| CUSIP | 45337C102 |
| Location | Delaware; U.S.A |
| Business Address | 1801 Augustine Cut-Off, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.incyte.com |
| Phone | 302 498 6700 |
| Currency | USD - US Dollar |
Incyte Key Financial Ratios
| Return On Equity | 0.008 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.15 % | ||||
| Price To Sales | 3.33 X | ||||
| Revenue | 3.7 B |
Incyte Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 3.4B | 3.6B | 4.9B | 5.8B | 6.8B | 7.1B | |
| Other Current Liab | 76.1M | 517.5M | 669.0M | 861.0M | 1.1B | 1.1B | |
| Net Debt | (1.8B) | (1.5B) | (2.0B) | (2.9B) | (3.2B) | (3.0B) | |
| Retained Earnings | (1.4B) | (1.7B) | (777.9M) | (437.2M) | 160.4M | 168.4M | |
| Accounts Payable | 83.6M | 98.8M | 172.1M | 277.5M | 109.6M | 115.1M | |
| Cash | 1.8B | 1.5B | 2.1B | 3.0B | 3.2B | 3.4B | |
| Other Current Assets | 94.2M | 60.1M | 126.3M | 167.0M | 182.8M | 192.0M | |
| Total Liab | 828.3M | 949.7M | 1.2B | 1.5B | 1.6B | 1.7B | |
| Total Current Assets | 2.5B | 2.4B | 3.2B | 4.2B | 4.6B | 4.9B | |
| Short Term Debt | 28.3M | 15.0M | 13.2M | 11.4M | 9.1M | 8.7M | |
| Net Receivables | 308.8M | 482.0M | 616.3M | 644.9M | 743.6M | 780.7M | |
| Intangible Assets | 193.8M | 172.3M | 150.8M | 129.2M | 123.5M | 74.2M | |
| Other Assets | 55.6M | 25.1M | 467.5M | 564.0M | 648.6M | 681.1M | |
| Common Stock | 216K | 219K | 221K | 223K | 224K | 157.9K | |
| Other Liab | 271.2M | 266M | 244M | 269.6M | 310.0M | 156.9M | |
| Inventory | 16.5M | 36.0M | 56.9M | 121.0M | 63.0M | 66.1M | |
| Net Tangible Assets | 2.2B | 2.3B | 3.5B | 4.1B | 4.7B | 4.9B | |
| Capital Surpluse | 4.0B | 4.4B | 4.6B | 4.8B | 5.5B | 3.4B |
Incyte Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 1.9M | 2.2M | 1.9M | 2.7M | 2.6M | 2.4M | |
| Total Revenue | 2.2B | 2.7B | 3.0B | 3.4B | 3.7B | 3.9B | |
| Gross Profit | 2.0B | 2.5B | 2.8B | 3.2B | 3.4B | 3.6B | |
| Operating Income | 402.0M | (240.3M) | 585.8M | 579.4M | 620.5M | 651.6M | |
| Ebit | 402.0M | (230.0M) | 572.4M | 531.8M | 836.8M | 878.6M | |
| Ebitda | 473.9M | (178.2M) | 630.2M | 599.6M | 919.4M | 965.4M | |
| Cost Of Revenue | 114.2M | 131.3M | 151.0M | 207.0M | 255M | 267.8M | |
| Income Before Tax | 486.8M | (232.2M) | 570.4M | 529.1M | 834.2M | 875.9M | |
| Net Income | 446.9M | (295.7M) | 948.6M | 340.7M | 597.6M | 627.5M | |
| Income Tax Expense | 39.9M | 63.5M | (378.1M) | 188.5M | 236.6M | 248.4M | |
| Research Development | 1.2B | 2.2B | 1.5B | 1.6B | 1.6B | 1.7B | |
| Tax Provision | 39.9M | 63.5M | (378.1M) | 188.5M | 218.9M | 229.8M | |
| Interest Income | 45.6M | 84.8M | 10.6M | 39.9M | 172.3M | 181.0M | |
| Net Interest Income | (1.9M) | (2.2M) | (1.9M) | (2.7M) | 106.2M | 111.5M |
Incyte Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Incyte. It measures of how well Incyte is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Incyte brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Incyte had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Incyte has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 668.7M | (318.9M) | 544.4M | 894.0M | 262.1M | 275.2M | |
| Free Cash Flow | 632.6M | (312.0M) | 568.5M | 892.1M | 449.0M | 471.5M | |
| Depreciation | 54.5M | 51.8M | 57.8M | 67.9M | 82.7M | 86.8M | |
| Other Non Cash Items | (14.3M) | 13.5M | 40.2M | 117.1M | 7.9M | 7.5M | |
| Capital Expenditures | 78.1M | 187.4M | 181.0M | 77.8M | 47.5M | 42.9M | |
| Net Income | 446.9M | (295.7M) | 948.6M | 340.7M | 597.6M | 627.5M | |
| End Period Cash Flow | 1.8B | 1.5B | 2.1B | 3.0B | 3.2B | 3.4B | |
| Change To Inventory | (6.1M) | (19.5M) | (21.0M) | (67.5M) | (170.2M) | (178.7M) | |
| Investments | (9.4M) | (81.6M) | (26.7M) | (709K) | (74.1M) | (77.8M) | |
| Change Receivables | (1.2M) | (173.2M) | (134.3M) | (28.6M) | (25.7M) | (27.0M) | |
| Change To Netincome | 186.4M | 201.5M | (266.4M) | 275.0M | 316.3M | 332.1M |
Incyte Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Incyte's current stock value. Our valuation model uses many indicators to compare Incyte value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Incyte competition to find correlations between indicators driving Incyte's intrinsic value. More Info.Incyte is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Incyte's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Incyte's earnings, one of the primary drivers of an investment's value.Incyte Systematic Risk
Incyte's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Incyte volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Incyte correlated with the market. If Beta is less than 0 Incyte generally moves in the opposite direction as compared to the market. If Incyte Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Incyte is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Incyte is generally in the same direction as the market. If Beta > 1 Incyte moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Incyte Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Incyte's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Incyte growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Incyte November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Incyte help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Incyte. We use our internally-developed statistical techniques to arrive at the intrinsic value of Incyte based on widely used predictive technical indicators. In general, we focus on analyzing Incyte Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Incyte's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.27 | |||
| Information Ratio | 0.0246 | |||
| Maximum Drawdown | 20.37 | |||
| Value At Risk | (2.70) | |||
| Potential Upside | 3.02 |
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.